IMC-F106C
2 products
2 abstracts
Abstract
Phase 1 safety and efficacy of IMC-F106C, a PRAME × CD3 ImmTAC bispecific, in post-checkpoint cutaneous melanoma (CM).Org: The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, Los Angeles, CA, HCA Healthcare global Sarah Cannon Research Institute, London, United Kingdom, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom, University of Chicago, Comprehensive Cancer Center, Chicago, IL, Jefferson Medical College, Philadelphia, PA,
Abstract
A phase 3 trial of IMC-F106C (PRAME x CD3) plus nivolumab versus standard nivolumab regimens in HLA-A*02:01+ patients with previously untreated advanced melanoma (PRISM-MEL-301).Org: Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Department of Dermatology, University Hospital St. Pölten, Karl Landsteiner University of Health Sciences, Greenville Health System, Abindgon,
Product
IMC-F106C + PembrolizumabProduct
IMC-F106C and Pembrolizumab